/TLPPF

TLPPF Stock - Telix Pharmaceuticals Limited

Q: What is the analyst price target for TLPPF?

Analyst price target information is not currently available for TLPPF.

Q: What is TLPPF's market cap?

Market capitalization information is not currently available for TLPPF.

Healthcare|Biotechnology|OTC

$7.50-2.22%

$0.17 (-2.22%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $8.25

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TLPPF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.15

52W High$24.85

52W Low$6.95

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$783.21M	$502.55M	$160.10M	$7.60M	$5.21M
Gross Profit	$509.68M	$314.39M	$29.34M	$-29,765,000	$-16,877,000
Gross Margin	65.1%	62.6%	18.3%	-391.9%	-323.7%
Operating Income	$82.13M	$51.89M	$-91,930,000	$-81,247,000	$-49,253,000
Net Income	$49.92M	$5.21M	$-104,079,000	$-80,510,000	$-44,887,000
Net Margin	6.4%	1.0%	-65.0%	-1059.9%	-861.1%
EPS	$0.15	$0.02	$-0.34	$-0.29	$-0.17

Company Overview

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Visit Website

Earnings History & Surprises

TLPPF

Beat Rate

Last 11 quarters

Avg Surprise

-110.3%

EPS vs Estimate

Beats / Misses

0/11

Last 12 quarters

Latest EPS

$-0.01

Q3 2025

EPS Surprise History

Q4 21

-120.1%

$-0.12vs$-0.06

Q2 22

-94.4%

$-0.16vs$-0.08

Q4 22

-44.1%

$-0.07vs$-0.05

Q2 23

-180.7%

$-0.03vs$0.04

Q2 24

No data

Q3 24

-75.4%

$0.02vs$0.09

Q1 25

-24.2%

$0.07vs$0.09

Q3 25

-105.1%

$-0.01vs$0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 18, 2026	—	—	—	—
Q3 2025	Aug 20, 2025	$0.13	$-0.01	-105.1%	✗ MISS
Q1 2025	Feb 20, 2025	$0.09	$0.07	-24.2%	✗ MISS
Q3 2024	Aug 22, 2024	$0.09	$0.02	-75.4%	✗ MISS
Q2 2024	May 22, 2024	—	$0.04	—	—
Q2 2023	Jun 30, 2023	$0.04	$-0.03	-180.7%	✗ MISS
Q4 2022	Dec 31, 2022	$-0.05	$-0.07	-44.1%	✗ MISS
Q2 2022	Jun 30, 2022	$-0.08	$-0.16	-94.4%	✗ MISS
Q4 2021	Dec 31, 2021	$-0.06	$-0.12	-120.1%	✗ MISS
Q2 2021	Jun 30, 2021	$-0.09	$-0.09	-0.6%	✗ MISS
Q4 2020	Dec 31, 2020	$0.07	$-0.08	-208.1%	✗ MISS
Q2 2020	Jun 30, 2020	$-0.04	$-0.05	-11.8%	✗ MISS
Q4 2019	Dec 31, 2019	$-0.01	$-0.05	-349.4%	✗ MISS
Q2 2019	Jun 30, 2019	—	$-0.03	—	—
Q4 2018	Dec 31, 2018	—	$-0.03	—	—
Q2 2018	Jun 30, 2018	—	$-0.02	—	—
Q4 2017	Dec 31, 2017	—	$-0.01	—	—
Q2 2017	Jun 30, 2017	—	$-0.02	—	—
Q1 2017	Jan 31, 2017	—	$-0.01	—	—
Q2 2016	Jun 30, 2016	—	$0.01	—	—

Frequently Asked Questions about TLPPF

What is TLPPF's current stock price?

Telix Pharmaceuticals Limited (TLPPF) is currently trading at $7.50 per share. The stock has moved -2.22% today.

What is the analyst price target for TLPPF?

No analyst price targets are currently available for this stock.

What sector is Telix Pharmaceuticals Limited in?

Telix Pharmaceuticals Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is TLPPF's market cap?

Telix Pharmaceuticals Limited has a market capitalization of $2.54 billion, making it a mid-cap company.

Does TLPPF pay dividends?

No, Telix Pharmaceuticals Limited does not currently pay a dividend to shareholders.